<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669133</url>
  </required_header>
  <id_info>
    <org_study_id>1807274844</org_study_id>
    <nct_id>NCT03669133</nct_id>
  </id_info>
  <brief_title>Vitamin E for NASH Treatment in HIV Infected Individuals</brief_title>
  <official_title>Vitamin E for NASH Treatment in HIV Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how taking Vitamin E daily affects fatty liver in persons&#xD;
      living with HIV. Subjects will have both HIV and a fatty liver and the purpose of the study&#xD;
      is to learn if underlying liver condition (fatty liver) gets better, worse, or stays the same&#xD;
      from taking Vitamin E.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a proof-of-concept clinical trial to evaluate the efficacy of&#xD;
      vitamin E for treatment of non-alcoholic steatohepatitis (NASH) in persons living with HIV.&#xD;
      Hypothesis: Vitamin E will improve radiographically measured hepatic fat content and&#xD;
      circulating markers of liver inflammation and injury in persons living with HIV who have&#xD;
      NASH.&#xD;
&#xD;
      A. Perform a pilot randomized placebo controlled trial of vitamin E 800 IU/daily for 6 months&#xD;
      in 56 persons living with HIV with biopsy-proven NASH B. Measure change in liver fat content&#xD;
      by magnetic resonance proton-density fat fraction (Primary outcome) C. Determine the impact&#xD;
      of vitamin E treatment on noninvasive markers of hepatic and systemic inflammation, hepatic&#xD;
      fibrosis, and systemic oxidative stress (Secondary outcomes) D. Define baseline hepatic gene&#xD;
      expression signatures predictive of response to therapy.&#xD;
&#xD;
      Upon completion, the proposed clinical trial may establish vitamin E as an excellent and&#xD;
      inexpensive candidate for further development as a treatment for NASH in persons living with&#xD;
      HIV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A: Vitamin E 800 IU/daily for 24 weeks. (total of 28 subjects) Group B: Matching placebo for 24 weeks (total of 28 subjects)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Study biostatistician and Investigational Drug Services pharmacist will randomize subjects and will provide study drug</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Measure % change in liver fat content by magnetic resonance proton-density fat fraction</measure>
    <time_frame>at randomization visit (study day 1) and end of study visit (week 24)</time_frame>
    <description>MRI at randomization and completion visits to assess liver steatosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of vitamin E treatment on noninvasive markers of hepatic inflammation</measure>
    <time_frame>at randomization visit (study day 1) and end of study visit (week 24)</time_frame>
    <description>ALT(IU/L), AST (IU/L) , cytokeratin-18 (IU/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of vitamin E treatment on noninvasive markers of systemic inflammation</measure>
    <time_frame>at randomization visit (study day 1) and end of study visit (week 24)</time_frame>
    <description>TNF-alpha (pg/L), IL-10 (pg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of vitamin E treatment on noninvasive markers of hepatic fibrosis</measure>
    <time_frame>at randomization visit (study day 1) and end of study visit (week 24)</time_frame>
    <description>liver stiffness by fibroscan (kPa)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>NAFLD</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin E 800 IU/daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <description>Vitamin E 800 IU/daily</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Matching placebo daily</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. males and females ≥18 years with biopsy-proven NASH within 6 months prior to&#xD;
             enrollment&#xD;
&#xD;
          2. histological diagnosis of NASH will be confirmed by an experienced liver pathologist&#xD;
             before study entry&#xD;
&#xD;
          3. HIV infection&#xD;
&#xD;
          4. stable dose of anti-diabetic agents and ART in the 3 months preceding enrollment and&#xD;
             expected by the physician treating diabetes and HIV to remain on stable medications&#xD;
             during the study&#xD;
&#xD;
          5. willingness to participate in the study&#xD;
&#xD;
          6. ability to understand and give informed consent for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of other chronic liver diseases (hepatitis B or C, autoimmune hepatitis,&#xD;
             cholestatic liver disease, Wilson disease, hemochromatosis, etc.)&#xD;
&#xD;
          2. average alcohol consumption &gt;3 drinks/day for men or &gt;2 drinks/day for women in the 6&#xD;
             months prior to enrollment.&#xD;
&#xD;
          3. Alcohol Use Disorder Identification Test (AUDIT) score of ≥8&#xD;
&#xD;
          4. evidence of cirrhosis on histology or imaging&#xD;
&#xD;
          5. ongoing use of medications known to cause hepatic steatosis (e.g., corticosteroids,&#xD;
             amiodarone, methotrexate, tetracycline, tamoxifen, estrogens at doses greater than&#xD;
             those used for birth control, anabolic steroids, or valproic acid)&#xD;
&#xD;
          6. prior bariatric surgery&#xD;
&#xD;
          7. severe co-morbidities (e.g., advanced cardiac, renal, pulmonary, or psychiatric&#xD;
             illness)&#xD;
&#xD;
          8. allergy to vitamin E&#xD;
&#xD;
          9. use of vitamin E or multivitamins containing vitamin E in the three months preceding&#xD;
             enrollment&#xD;
&#xD;
         10. use of drugs with potential effect on NASH such as ursodeoxycholic acid,&#xD;
             S-adenosylmethionine (SAM-e), betaine, pentoxifylline, or milk thistle in the three&#xD;
             months prior to enrollment.&#xD;
&#xD;
         11. changing doses of statins (simvastatin, pravastatin, atorvastatin, fluvastatin,&#xD;
             lovastatin, rosuvastatin) or fibrates (clofibrate, fenofibrate) in the three months&#xD;
             prior enrollment.&#xD;
&#xD;
         12. illicit substance abuse within the past twelve months&#xD;
&#xD;
         13. breast feeding, pregnancy, inability or unwillingness to practice contraception for&#xD;
             the duration of the study&#xD;
&#xD;
         14. contraindications for the MRI procedure (e.g., prostheses, severe claustrophobia)&#xD;
&#xD;
         15. poorly controlled diabetes with A1C &gt;8.5 within in the last six months&#xD;
&#xD;
         16. use of total parenteral nutrition in the 6 months preceding liver biopsy or enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samer Gawrieh, MD</last_name>
    <phone>317-278-9326</phone>
    <email>sgawrieh@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regina Weber, BS, RRT</last_name>
    <phone>317-278-3584</phone>
    <email>reginaw@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montreca Robison</last_name>
      <phone>317-278-0408</phone>
      <email>mgrobiso@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Regina Weber, BS, RRT</last_name>
      <phone>317-278-3584</phone>
      <email>reginaw@iu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen E Corey, MD</last_name>
      <email>Kathleen.Corey@MGH.HARVARD.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Jenna L Gustafson</last_name>
      <phone>(617)724-3836</phone>
      <email>jlgustafson@partners.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University School of Medicine</investigator_affiliation>
    <investigator_full_name>Samer Gawrieh</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Fatty liver</keyword>
  <keyword>NAFLD</keyword>
  <keyword>NASH</keyword>
  <keyword>HIV</keyword>
  <keyword>Vitamin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

